Tirzepatide
Mounjaro (T2D), Zepbound (obesity/OSA); LY3298176; "tirz"
The Ground Truth Score
four plain questions, never one numberFDA-approved dual incretin with the strongest weight-loss RCT data in class, real risks, not a research peptide
Bottom line
Among the most rigorously proven compounds on this site, multiple large RCTs and FDA approval back ~20% weight loss, but a boxed thyroid-tumor warning, MEN2 contraindication, and heavy GI burden mean it is a prescription drug, not a casual peptide.
Does the science back it?
Do real people feel it?
Is it safe?
Could it be placebo?
Can you legally get it?
FDA-approvedPrescription medicineAn approved drug with a label, a manufacturer, and a prescribing route. This is the only tier where what is in the vial is guaranteed by anyone. Check the indication, though: approval is always for something specific, and it is rarely the use this compound is popular for.
Approved by FDA (Mounjaro/Zepbound). Same April 2026 proposal narrows its compounded route.
Legal status as of 2026-04-30. This is a separate axis from the grades above, and it does not move them. A vote about who may legally prepare a compound is not evidence that the compound works.
"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.
Why is the evidence this thin? It's mostly economics →
Dose at a glance
full dosing ↓Label titration (Zepbound/Mounjaro): start 2.5 mg SC once weekly for 4 weeks (tolerability lead-in, not therapeutic), increase to 5 mg, then step up in 2.5 mg increments no more often than every 4 weeks as tolerated; maintenance 5, 10, or 15 mg once weekly.
Reported, not prescribed. Verify your vial and your math.
First documented human use
Phase 1 first-in-human dosing ~2017; pivotal evidence from SURPASS (T2D) and SURMOUNT (obesity) phase 3 programs 2021-2023. FDA-approved as Mounjaro for type 2 diabetes May 13, 2022; as Zepbound for chronic weight management Nov 8, 2023; for moderate-severe obstructive sleep apnea in 2024.
The pitch
What people claim it does
Stated plainly and neutrally, exactly as you'll hear it. We grade each one below.
- Once-weekly dual GIP + GLP-1 receptor agonist that produced ~21% mean weight loss at the 15 mg dose over 72 weeks in SURMOUNT-1 (vs 3.1% placebo), the largest effect of any approved obesity drug to date.
- Head-to-head SURMOUNT-5 showed superiority over semaglutide for weight loss, and SURPASS-CVOT (NEJM, Dec 2025) demonstrated cardiovascular non-inferiority vs dulaglutide with a signal toward lower all-cause mortality.
- Unlike most compounds profiled here, it is genuinely FDA-approved with a known mechanism, defined pharmacokinetics, and a quality-controlled commercial supply, the evidence is real, not extrapolated from rodents.
The data behind each bullet
What actually backs it
Produced ~20.9% mean body-weight reduction at 15 mg over 72 weeks in adults with obesity (SURMOUNT-1), vs 3.1% on placebo.
SURMOUNT-1, double-blind placebo-controlled phase 3 RCT (N=2,539), published NEJM 2022 (PMID 35658024).
PubMed: SURMOUNT-1 (NEJM 2022) ↗Superior weight loss vs semaglutide 2.4 mg in a 72-week head-to-head randomized trial (SURMOUNT-5).
SURMOUNT-5, randomized open-label phase 3b head-to-head trial; published 2025.
PubMed: SURMOUNT-5 tirzepatide vs semaglutide ↗Cardiovascular non-inferiority for 3-point MACE vs dulaglutide (an agent with proven CV benefit) in 13,299 T2D patients, with a directional reduction in all-cause mortality.
SURPASS-CVOT, randomized double-blind event-driven trial; full results published NEJM Dec 2025.
PubMed: SURPASS-CVOT tirzepatide ↗Associated with increased gallbladder/biliary disease (meta-analysis RR ~1.97, 95% CI 1.14-3.42).
Meta-analysis of 9 RCTs of tirzepatide vs placebo/basal insulin.
PubMed: tirzepatide gallbladder biliary meta-analysis ↗Causes dose- and duration-dependent thyroid C-cell tumors (adenomas/carcinomas) in rats; human relevance undetermined.
2-year rat carcinogenicity study cited in FDA label boxed warning; human MTC risk unknown (animal-only data).
FDA Label: Mounjaro (boxed warning) ↗Prove it
Can you tell if it's working?
The honest test: if it's working, is there any objective way to see it — a blood marker, a scan, a wearable? For a lot of peptides the answer is no, and that's worth knowing before you spend on labs or gear.
DEXA (fat mass + visceral fat, plus lean-mass safety) alongside waist/weight is direct, validated proof it's working; CGM and a home sleep-apnea test add efficacy signal only in the users those apply to.
Bloodwork
A routine lab actually tracks whether this is working.
Tirzepatide is a dual GIP/GLP-1 receptor agonist whose pharmacological action is glucose homeostasis itself: it enhances glucose-dependent insulin secretion, improves insulin sensitivity, blunts postprandial glucose, and drives fat-mass loss. Those effects are exactly what routine glycemic and lipid labs measure, so a working dose leaves a clear fingerprint in standard bloodwork (this is efficacy, not mere drug presence). Direct verification is real in hyperglycemic users; in a euglycemic weight-loss user the glycemic signal is muted and the cleanest efficacy readout (body weight/waist) is not bloodwork.
In T2D/prediabetic users, a meaningful drop toward or into the normal range (<5.7%); SURPASS trial-average baseline ~8.3% fell substantially on all doses. In an already-euglycemic weight-loss user, HbA1c starts near-normal and moves little, so it is a weak proof of action in that population.
Reflects 3-month average glucose, which falls as tirzepatide restores glucose-dependent insulin secretion and insulin sensitivity; this is the registered FDA trial efficacy endpoint.
Fasting glucose declines toward the normal range in hyperglycemic users; minimal change if already euglycemic.
Direct readout of the improved beta-cell response and reduced hepatic glucose output the drug produces.
Fasting insulin and calculated HOMA-IR/HOMA2-IR fall as insulin sensitivity improves; documented in SURPASS-2 (HOMA2-IR down, HOMA2-B up). Fasting insulin is noisier than HbA1c, so read it as a trend alongside glucose, not a single-draw verdict.
Tirzepatide improves insulin sensitivity and islet-cell function, so the body needs less circulating insulin for the same glucose.
Fasting triglycerides typically fall with weight/fat loss and improved insulin sensitivity; HDL may edge up modestly. Directionally supportive corroboration, not a primary proof.
Improved insulin sensitivity and reduced adiposity lower VLDL/triglyceride output; useful corroborating signal.
Draw baseline
Before the first dose (or at least before any dose escalation), fasting.
Retest
8-12 weeks, drawn after the user has reached and held a stable therapeutic maintenance dose (titration runs several weeks, so retesting mid-titration understates effect).
Read this before you spend on labs
This is one of the few peptides with genuinely direct blood verification, but the caveat is population-dependent. In diabetic/prediabetic users, HbA1c and fasting glucose are clean, established proof it is working (HbA1c is the actual FDA-trial efficacy endpoint). In a metabolically healthy person taking it purely for weight loss, those glycemic markers often start normal and barely move, so bloodwork is a weak efficacy proof there; fasting insulin/HOMA-IR and triglycerides usually still improve with fat loss and are the better labs in that group, but the most direct efficacy readout in a euglycemic user is body weight/waist circumference, which is not bloodwork. Confirm labs are fasting and avoid drawing during acute GI side-effect/reduced-intake periods, which can transiently distort glucose.
Other ways to track it
Whole-body DEXA scan — total fat mass, visceral adipose tissue (VAT), and lean/appendicular muscle mass
A working result shows a clear drop in total fat mass and a proportionally larger drop in VAT. DEXA's second job is catching the downside: some lean/muscle mass is lost with the fat (roughly a quarter of total weight lost was lean tissue in SURMOUNT-1's DXA substudy), so the goal is flat-or-preserved lean mass via resistance training + high protein. Do not read minor lean-mass loss as the drug failing — read it as a cue to protect muscle.
Tirzepatide is a dual GIP/GLP-1 agonist that drives large fat-mass and visceral-fat loss. DEXA is the validated, orderable scan that partitions fat vs lean and isolates VAT (the metabolically dangerous depot); SURMOUNT-1's DXA substudy showed a large VAT reduction (~40% at 72 weeks).
Tape-measure waist circumference + home scale (home BP cuff as a supporting readout)
The most direct at-home efficacy signal: steady waist-circumference and body-weight decline over weeks to months. Waist is the cheap proxy for the visceral fat DEXA measures. Blood pressure also tends to fall as weight comes off (documented in SURMOUNT ambulatory-BP data), so a home cuff trending down is a supporting sign — though it is nonspecific to weight loss generally.
Body weight is the primary endpoint of the SURMOUNT program, so in a metabolically healthy user the single most direct efficacy readout is weight / waist circumference, not bloodwork — waist tracks visceral fat between the more expensive DEXA scans.
14-day continuous glucose monitor — mean glucose, time-in-range, glycemic variability (SD/CV), post-meal excursions
In a prediabetic/diabetic user, a working result shows lower mean glucose, flatter post-meal spikes, tighter variability, and more time-in-range — a genuine efficacy signal. In an already-euglycemic user glucose typically starts normal and barely moves, so a flat CGM does NOT mean the drug isn't working; in that person fat mass and waist are the real endpoint.
As a GIP/GLP-1 agonist tirzepatide slows gastric emptying and enhances glucose-dependent insulin secretion, lowering glucose — an effect that is only clearly visible on CGM in someone who is dysglycemic to begin with.
Home sleep apnea test (WatchPAT/HSAT) — apnea-hypopnea index (AHI); Oura/WHOOP resting HR, nocturnal SpO2 dips, and HRV as weak adjuncts
Only meaningful if you actually have obstructive sleep apnea. A validated home sleep-apnea test can show a real, large drop in AHI as weight falls (the SURMOUNT-OSA RCTs showed roughly 50-60% AHI reductions and disease resolution in about half of highest-dose participants). Consumer wearables only weakly proxy this: resting HR trending down and fewer nocturnal SpO2 desaturations are supportive but nonspecific to weight loss, and deep-sleep/HRV changes are noisy — the wearable is not a substitute for an HSAT here.
Tirzepatide significantly reduced OSA severity in the SURMOUNT-OSA RCT, driven by loss of fat (including pharyngeal and visceral fat). AHI on a home sleep apnea test is the objective efficacy readout; wearable metrics are secondary and confounded.
Bottom line
Tirzepatide is one of the most objectively trackable peptides, so almost every honest signal is non-blood. DEXA is the standout: it proves fat and visceral-fat loss AND flags the real risk — lean/muscle loss — which no blood marker catches. Waist + weight is the cheap direct proxy in between scans. The caveats: CGM only clearly moves in prediabetic/diabetic users (a flat CGM in a metabolically healthy person is not failure — fat mass is the endpoint), and the sleep-apnea signal only applies if you have OSA and is best measured by a home sleep apnea test rather than an Oura/WHOOP wearable. Blood (HbA1c, fasting glucose, insulin, triglycerides) is already covered and remains a direct readout in dysglycemic users.
Logging baseline vs retest is the whole game. The Truth Tracker is our free log for bloodwork, DEXA, genetics, and wearable data — bring your own numbers.
How to track it →Mechanism
How it's assumed to work
Assumed · theoretical pathway
Confirmed (approved): dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Enhances glucose-dependent insulin secretion, slows gastric emptying, and acts centrally to reduce appetite/food intake; the GIP component is thought to add to GLP-1 effects on weight and may improve GI tolerability relative to GLP-1 alone.
Dosing & handling
What users and clinicians report
Label titration (Zepbound/Mounjaro): start 2.5 mg SC once weekly for 4 weeks (tolerability lead-in, not therapeutic), increase to 5 mg, then step up in 2.5 mg increments no more often than every 4 weeks as tolerated; maintenance 5, 10, or 15 mg once weekly. Higher doses give more weight loss (meta-regression ~ -0.72% body weight per additional 1 mg) but more GI burden.
REPORTED, not prescribed, this is a prescription drug that must be dosed and monitored by a clinician. Do NOT escalate rapidly: case reports document severe hypoglycemia, ICU-level complications, and even ventricular fibrillation from unsupervised high-dose or fast-titration use. Compounded/gray-market vials carry real risk of mislabeled concentration and dosing-error overdose. Verify vial concentration before any math.
Timing & food
Once weekly on the same day, any time of day, with or without food (food does not meaningfully affect absorption). Injected subcutaneously into abdomen, thigh, or upper arm with site rotation. Day can be changed as long as doses are >=3 days apart. Many users pick a day where next-day GI side effects are least disruptive.
Half-life
~5 days (approximately 120 hours), enabling once-weekly subcutaneous dosing. Steady state is reached in about 4 weeks (~4-5 half-lives), which is why each titration step is held ~4 weeks.
Reconstitution sensitivity
Commercial product ships as a ready-to-use single-dose pen/vial or a KwikPen, no reconstitution needed; refrigerate (excursions to room temperature are time-limited per label). Compounded/lyophilized "research" tirzepatide does require reconstitution with bacteriostatic water and is the main source of dosing errors and contamination risk, confirm the labeled mg-per-vial and resulting concentration before drawing any dose.
Real-world signal
What people actually report
Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.
Volume
Very high. One analysis of ~410,000 Reddit posts (2019-2025) identified ~67,000 self-reported tirzepatide users; mainstream media, dedicated GLP-1/Zepbound/Mounjaro communities, and large medspa/telehealth patient bases generate enormous discussion volume.
Consistency
Highly consistent on the two headline themes: large, often dramatic weight loss, and frequent GI side effects (nausea/constipation/"sulfur burps") concentrated during titration. Consistent secondary reports of appetite/"food noise" reduction. More variable reports on fatigue, hair shedding, muscle-loss anxiety, and weight regain after stopping.
Source credibility
Moderate-to-high but mixed in source quality. The community signal is corroborated by the trial and FAERS data (so it is unusually credible for this site), but much online content is affiliate-driven (compounding pharmacies, telehealth funnels, "peptide catalog" vendors) and should be discounted; weight the RCT/FDA evidence above any forum claim.
- Overwhelmingly positive on efficacy: users routinely report substantial, steady weight loss and a marked drop in appetite/'food noise' that makes a calorie deficit feel effortless.
- GI side effects are the dominant complaint, nausea, constipation, and 'sulfur burps' especially during dose increases; most describe them as manageable and fading at a stable dose, a minority stop because of them.
- Recurring anxiety about losing muscle and about weight regain after discontinuation; experienced users emphasize protein intake and resistance training, and many plan a maintenance dose rather than stopping cold.
- Active caution within communities about compounded/gray-market sourcing, concentration errors, supply interruptions, and rapid self-titration are repeatedly flagged as causes of bad outcomes.
Placebo risk, Low
The primary endpoint, body weight, is objective and measured on a scale, and the effect size (~15-21%) dwarfs the placebo arm (~3%), so the benefit is not plausibly placebo. Appetite suppression is also corroborated by objective intake-reduction data. Subjective elements (energy, mood) carry some expectancy effect, but the core result is firmly objective.
Risk panel
What could go wrong
Adverse events
Gastrointestinal events dominate and are common: across SURMOUNT-1 to -4, nausea ~25-36%, diarrhea ~21%, constipation ~21%, vomiting ~16%, mostly mild-moderate and concentrated during dose escalation. Treatment discontinuation for GI events ran roughly 1-10.5% depending on dose/trial. Decreased appetite, fatigue, injection-site reactions, and transient heart-rate increase also reported.
Theoretical concerns
Lean-mass loss accompanies rapid weight loss (imaging data suggest muscle-volume loss largely tracks total weight loss rather than being disproportionate, but resistance training and adequate protein are prudent); gallbladder/biliary disease is a measurable elevated risk; rare but reported acute pancreatitis; rapid or unsupervised dose escalation has caused severe hypoglycemia and life-threatening GI complications in case reports. Long-term (>5 yr) human safety and effects of indefinite use are still accruing.
Contraindications
BOXED WARNING for thyroid C-cell tumors (rat data). Contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and in known serious hypersensitivity. Caution/avoid with prior pancreatitis, severe gastroparesis, history of gallbladder disease, and in pregnancy. Risk of hypoglycemia rises when combined with insulin or sulfonylureas.
Honest unknowns
Whether the rodent thyroid C-cell tumor signal translates to human medullary thyroid carcinoma risk is undetermined. Durability after discontinuation (weight regain is common once stopped), optimal long-term maintenance dosing, effects of multi-year continuous use, and the safety/identity of compounded or gray-market "research" tirzepatide (no quality control, mislabeled concentration, dosing-error overdoses) are all open concerns.
Confound watch
Pivotal trials paired the drug with lifestyle intervention (diet + activity), and SURMOUNT-3 layered it on top of an intensive lifestyle lead-in, so some benefit reflects co-interventions, not drug alone. Real-world users frequently stack it with TRT, other peptides, caloric restriction, and resistance training, confounding attribution. Forum reports skew toward early responders; appetite suppression makes adherence to a calorie deficit easier, which independently drives the result.
History
Discovery → first use → status
- ~2017First-in-human phase 1 dosing of LY3298176 (tirzepatide) by Eli Lilly.
- 2021SURPASS phase 3 program (type 2 diabetes) reports superior A1C and weight reduction vs comparators.
- 2022-06SURMOUNT-1 obesity RCT published in NEJM: ~20.9% weight loss at 15 mg over 72 weeks (PMID 35658024).
- 2022-05-13FDA approves Mounjaro for type 2 diabetes.
- 2023-11-08FDA approves Zepbound for chronic weight management in obesity/overweight with a comorbidity.
- 2024FDA approves Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity.
- 2025-12SURPASS-CVOT full cardiovascular outcomes published in NEJM: MACE non-inferior to dulaglutide, mortality signal favorable.
Verification
The COA standard, applied
FDA-approved with publicly available prescribing information (DailyMed/accessdata.fda.gov) and multiple peer-reviewed phase 3 RCTs in NEJM and The Lancet (SURMOUNT, SURPASS, SURPASS-CVOT). This is the rare profile where the headline claims are directly verifiable in regulatory documents and registered trials, not inferred.
The full verification standard →Sources
Where this comes from
- FDA Label - Mounjaro (tirzepatide), boxed warning & contraindications ↗· Authoritative prescribing information: GIP/GLP-1 mechanism, rat C-cell tumor boxed warning, MEN2/MTC contraindication, AE rates.
- FDA Label - Zepbound (tirzepatide) for weight management ↗· Obesity-indication label: titration schedule, dosing, warnings.
- PubMed - SURMOUNT-1 (NEJM 2022, PMID 35658024) ↗· Pivotal obesity RCT: ~20.9% weight loss at 15 mg vs 3.1% placebo over 72 weeks.
- PubMed - SURMOUNT-5 head-to-head vs semaglutide ↗· 72-week randomized head-to-head showing superior weight loss vs semaglutide 2.4 mg.
- PubMed - SURPASS-CVOT cardiovascular outcomes ↗· 13,299-patient CV outcomes trial (NEJM Dec 2025): MACE non-inferior to dulaglutide, favorable mortality signal.
- PubMed - tirzepatide gallbladder/biliary meta-analysis ↗· Meta-analysis of 9 RCTs: elevated gallbladder/biliary disease risk (RR ~1.97).
- PubMed - tirzepatide FAERS adverse-event analysis ↗· Real-world pharmacovigilance signals, including sex-specific subgroups.
- ClinicalTrials.gov - tirzepatide trial registry ↗· Registered SURPASS/SURMOUNT/SURPASS-CVOT trial records and protocols.
The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.